データなし
Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday
Corcept Therapeutics Files New Drug Application for Relacorilant
Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome
Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025?
Corcept Therapeutics Presents Phase 3 Long-Term Extension Study Of Relacorilant Demonstrated Durable Cardiometabolic Improvements In Patients With Hypercortisolism